ERBB3

Creative Biolabs focuses on providing advanced immune cell therapies to target and combat malignant diseases effectively. With our expertise in CAR-T cell technology, our team of experts is committed to supporting the development of innovative immune cell therapies targeting ERBB3-expressing cancers. We offer a variety of anti-ERBB3 CAR products to meet the diverse needs of researchers in the field of cancer immunotherapy.

Background

Human epidermal growth factor receptor 3 (ERBB3, HER3) is a receptor tyrosine kinase that plays a crucial role in cell growth, differentiation, and survival. It is a member of the ERBB family of receptor kinases, which includes EGFR (ERBB1), HER2 (ERBB2), and ERBB4. Dysregulation of ERBB3 signaling has been implicated in various cancers, including breast, ovarian, and prostate cancers, making it an attractive target for therapeutic intervention. Targeting ERBB3 with specific inhibitors, monoclonal antibodies or CAR-T therapy has shown promise in preclinical studies and clinical trials as a potential strategy for cancer therapy.

Associated Disease

• Prostate cancer
• Breast cancers
• Lung cancer
• Ovarian cancer

Anti-ERBB3 CAR-T Services

Anti-ERBB3 CAR-T In Vitro Assays

Creative Biolabs offers comprehensive in vitro assays to assess the efficacy and safety of anti-ERBB3 CAR-T cell therapy, including:

• Anti-ERBB3 CAR-T Expression Test

We provide anti-ERBB3 CAR-T expression test services that are used to determine the expression levels of CAR targeting the ERBB3 protein on T cells. Our experts utilize several molecular techniques such as WB, FC, and PCR to measure the expression levels of the CAR construct on the T cells.

Fig.1 The anti-ERBB3 CAR expression was detected by flow cytometry and western blot.¹

• Anti-ERBB3 CAR-T Proliferation Test

We utilize techniques such as cell counting, flow cytometry, and other cell proliferation assays to monitor and evaluate the proliferation of CAR-T cells. During the CAR-T proliferation test, CAR-T cells are typically cultured in vitro under controlled conditions and monitored over a specified period.

• Anti-ERBB3 CAR-T Cytokine Release Test

We offer comprehensive and accurate testing for evaluating the cytokine release in vitro. Our team of experts is well-equipped to deliver reliable and efficient results, ensuring the safety and efficacy of personalized cell therapy treatments.

Fig.2 The release of IL-2 and IFN-γ was detected by ELISA.¹

• Anti-ERBB3 CAR-T In Vitro Cytotoxicity Assay

We provide various anti-ERBB3 CAR-T cytotoxicity assays that are used to evaluate the cytotoxic activity of CAR-T cells against target cells, providing valuable information on the effectiveness of CAR-T cell therapy in killing tumor cells. Our team is dedicated to tailoring these tests to suit the specific requirements of each research project, ensuring accurate and reliable results for our clients.

Fig.3 The anti-ERBB3 CAR-T cytotoxicity against squamous cell carcinoma of the head and neck (SCCHN) tumor cells.¹

Anti-ERBB3 CAR-T In Vivo Assays

Efficacy Test of Anti-ERBB3 CAR-T

We provide comprehensive in vivo assays to evaluate the efficacy of anti-ERBB3 CAR-T cells in vivo. Our experts will monitor tumor growth, assess CAR-T cell persistence, and evaluate infiltration of CAR-T cells and overall anti-tumor response using a suitable animal model such as a mouse xenograft model.

Fig.4 In vivo antitumor activity of anti-ERBB3 CAR-T against a SCCHN xenograft.¹

Reference

1. Davies, David M., et al. "Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells." Molecular medicine 18.4 (2012): 565-576.